Zhejiang Qianjiang Biochemical Co (600796) Fair Value & Analysis
Basic Materials · CN · Market cap 4.4B CNY
Analysis
Zhejiang Qianjiang Biochemical Co (600796) currently trades at ¥4.93, while our model-based Fair Value estimate is ¥3.26 — implying the stock looks roughly 33.9% overvalued today. We read business quality at 90/100 (high quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
Zhejiang Qianjiang Biochemical Co., Ltd., together with its subsidiaries, research, develops, produces, sells, and services biopesticides in China and internationally. The company offers biopesticide products comprising plant growth regulators consisting of gibberellic acid and gibberellic acid A4+A7; insecticides, such as avermectin and emamectin benzoate; and fungicides, including jinggangmycin. It also provides ecological and environmental protection services, including the disposal and resource utilization of general solid and medical wastes, sludge, and kitchen waste, as well as sanitation and heat production services. In addition, the company offers water operation services comprising the protection and management of water environment; improvement of lakes and rivers; and investment, development, construction, operation, and management of water supply and drainage infrastructure, sewage treatment infrastructure, and related water projects. Further, it engages in the sale of st…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.